Research programme: SVP platform-based gene therapeutics - Spark Therapeutics

Drug Profile

Research programme: SVP platform-based gene therapeutics - Spark Therapeutics

Alternative Names: SVP platform-based factor VIII gene therapy - Spark Therapeutics; SVP platform-based FVIII gene therapy - Spark Therapeutics; SVP-Rapamycin plus FVIII gene therapy - Spark Therapeutics

Latest Information Update: 13 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Spark Therapeutics
  • Developer Selecta Biosciences; Spark Therapeutics
  • Class Blood coagulation factors; Gene therapies
  • Mechanism of Action Blood coagulation factor replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Haemophilia A

Most Recent Events

  • 05 Dec 2016 Spark Therapeutics in-licenses immune tolerance SVP™ platform technology from Selecta Biosciences
  • 05 Dec 2016 Early research in Haemophilia A in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top